Retatrutide (development code LY3437943) represents a significant advancement in metabolic research compounds. As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it has generated substantial interest in the research community. This guide covers everything Canadian researchers need to know about sourcing and studying Retatrutide in Canada.
Retatrutide is a synthetic peptide developed by Eli Lilly that functions as a triple receptor agonist. Unlike earlier compounds that target a single receptor pathway, Retatrutide simultaneously activates three distinct receptor systems: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
This triple mechanism distinguishes it from other metabolic research compounds such as Tirzepatide (dual GLP-1/GIP) and Semaglutide (GLP-1 only). The additional glucagon receptor activation introduces a unique dimension to metabolic research — glucagon stimulates energy expenditure through thermogenesis and fatty acid oxidation, potentially offering a more comprehensive research model for metabolic optimization.
Retatrutide's triple agonist activity works through three complementary pathways:
In clinical research, this triple mechanism has demonstrated significant effects on body weight and metabolic parameters. Studies published in peer-reviewed journals have reported substantial reductions in body weight over treatment periods, with the glucagon component contributing to increased energy expenditure not seen with dual agonists alone.
Key Research Finding: A Phase 2 clinical trial published in The Lancet (2023) reported that participants receiving Retatrutide experienced weight reductions of up to 24.2% at 48 weeks — the highest observed in clinical trials for this class of compounds at the time.
Canadian researchers are studying Retatrutide across several domains:
The primary area of investigation, focusing on energy metabolism, glucose homeostasis, and body composition. The triple agonist approach provides a more complete model for studying metabolic pathways than single or dual agonists.
The glucagon receptor component makes Retatrutide particularly valuable for research into thermogenesis and energy balance — areas where GLP-1-only compounds offer limited insight.
For researchers seeking Retatrutide Canada, domestic sourcing offers significant advantages over importing compounds. Vancouver Island Peptides provides Retatrutide synthesized at our Vancouver, BC lab partner — not imported from overseas. This ensures consistent purity, full traceability, and no customs delays.
Our Retatrutide is available in 10mg and 20mg vials, HPLC verified to >99% purity with full third-party lab reports. For researchers interested in higher-dose metabolic protocols, the 20mg variant offers extended research applications.
Note for Canadian Researchers: Retatrutide is not approved by Health Canada and is supplied strictly as a research compound for laboratory and personal wellness research purposes. All products from Vancouver Island Peptides are for research use only.
Understanding the differences between available research compounds is essential for designing effective protocols. Retatrutide Canada offers the broadest receptor targeting among GLP-based compounds, making it suitable for comprehensive metabolic research. Tirzepatide provides dual GLP-1/GIP activation and is available domestically through Canadian peptide suppliers. Semaglutide targets GLP-1 only and remains the most studied compound in its class, though its single-receptor mechanism offers a narrower research scope.
This content is for educational and research purposes only. Consult a qualified healthcare provider before use. Products are not approved by Health Canada.